乳腺癌乳房切除术后放射治疗的疗效分析
Efficacy of the Radiotherapy after Mastectomy in Breast Cancer

作者: 李云海 * , 王月琴 , 蒋 娉 , 沈海英 , 沈琰琦 , 李永春 , 夏 怡 , 罗伟明 , 朱 虹 , 肖 锋 :复旦大学附属肿瘤医院闵行分院放疗科,上海; 李 纲 :复旦大学附属肿瘤医院闵行分院化疗科,上海; 李 雷 :复旦大学附属肿瘤医院闵行分院乳腺外科,上海;

关键词: 乳腺肿瘤/外科学乳腺肿瘤/放射治疗预后Breast Neoplasms/Surgery Breast Neoplasms/Radiotherapy The Prognosis

摘要:
目的:总结乳腺癌乳房切除术后的放疗效果,并探讨相关预后影响因素。材料与方法:2005年1月至2012年12月共有241例入组,中位年龄51岁,最小27岁,最大75岁。0期1例,IA期11例,IIA期51例,IIB期41例,IIIA期82例,IIIB期3例,IIIC期42例,IV期10例。全组患者均接受乳房切除术,其中改良根治术210例,根治术29例,扩大根治术2例。除3例不详,其余患者均接受术后化疗,其中有50例接受新辅助化疗。全组患者均接受放射治疗,中位剂量50 Gy (30~60 Gy),照射部位包括同侧胸壁、淋巴引流区(锁骨上和/或内乳),147例照射同侧胸壁、锁骨上和内乳(61.0%),47例照射胸壁和锁骨上(19.5%),39例未照射胸壁,仅照射锁骨上和/或内乳(16.2%),6例仅照射胸壁(2.5%),2例照射胸壁和内乳(0.8%)。结果:中位随访5.5年(0~10年),全组5年OS为87.5%。单因素分析显示肿瘤分期是影响OS的重要因素(P = 0.002),I、II期的5年OS为95.9%,III、IV期的5年OS为81.0%。LRR有14例(5.8%),DM是主要失败原因,有49例(20.3%)。死亡36例,均死于肿瘤。结论:仅5.8%的复发,提示乳房切除术后的放射治疗仍是乳腺癌术后规范治疗标准,5年OS接近国内外先进水平。

Abstract: Objective: To summarize the outcome of radiotherapy in breast cancer after mastectomy, and to explore the relevant prognostic factors. Material and Methods: From January 2005 to December 2012, a total of 241 women who had undergone mastectomy were analyzed. The median age was 51 years old, with minimum 27 years old and maximum 75 years old. The pathological stage 0 were 1 case, IA of 11 cases, IIA of 51 cases, IIB of 41 cases, IIIA of 82 cases, IIIB of 3 cases, IIIC of 42 cases, IV of 10 cases, which performed in all patients by using AJCC 7th. All patients underwent mastectomy, which 210 cases of modified radical mastectomy, 29 cases of radical mastectomy, and 2 cases of extended radical mastectomy. In addition to three cases were unknown, the remaining patients received postoperative chemotherapy, while 50 patients received neoadjuvant chemotherapy. All patients were treated with radiation therapy, the median dose 50 Gy (30 - 60 Gy), irradiated sites included ipsilateral chest wall, lymph drainage area (supraclavicular and/or internal mammary). 147 cases were treated with chest wall, ipsilateral supraclavicular and internal mammary nodes irradiation (61.0%), 47 cases were treated with chest wall and supraclavicular irradiation (19.5%), 39 cases were treated with non-irradiated chest wall, only supraclavicular and/or internal mammary nodes (16.2%), 6 cases were only irradiated to chest wall (2.5%), two cases to chest wall and internal mammary irradiation (0.8%). Results: The median follow-up was 5.5 years (0 - 10 years), the 5-year OS was 87.5%. Univariate analysis showed that tumor stage was an important factor affecting the OS, 5-year OS of the pathological stage I and II was 95.9% while the OS of stage III and IV was 81.0% (P = 0.002). LRR in 14 cases (5.8%), whereas DM was the main causes of failure, which included 49 cases (20.3%). 36 patients died, all died of cancer. Conclusions Only 5.8% patients have locoregional recurrence, suggesting that radiation therapy after mastectomy is still the standard treatment in breast cancer. 5-year OS is approaching the world advanced level.

文章引用: 李云海 , 王月琴 , 蒋 娉 , 沈海英 , 沈琰琦 , 李永春 , 夏 怡 , 罗伟明 , 朱 虹 , 肖 锋 , 李 纲 , 李 雷 (2016) 乳腺癌乳房切除术后放射治疗的疗效分析。 世界肿瘤研究, 6, 8-13. doi: 10.12677/WJCR.2016.61002

参考文献

[1] Siegel, R., Ma, J.M., Zou, Z.H. and Jemal, A. (2014) Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29.
http://dx.doi.org/10.3322/caac.21208

[2] Zheng, R., Zeng, H., Zhang, S., et al. (2016) National Estimates of Cancer Prevalence in China, 2011. Cancer Letters, 370, 33-38.
http://dx.doi.org/10.1016/j.canlet.2015.10.003

[3] Early Breast Cancer Trialists Collaborative Group (1995) Effects of Radiotherapy and Surgery in Early Breast Cancer—An Overview of the Randomized Trials. The New England Journal of Medicine, 333, 1444-1456.
http://dx.doi.org/10.1056/NEJM199511303332202

[4] National Comprehensive Cancer Network (2015) NCCN Breast Cancer Guidelines (Version 2, 2015). NCCN, America.

[5] Recht, A., Edge, S.B., Solin, L.J., et al. (2001) Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1539-1569.

[6] Senkus, E., Kyriakides, S., Penault-Llorca, F., et al. (2013) Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, 7-23.
http://dx.doi.org/10.1093/annonc/mdt284

[7] Overgaard, M., Hansen, P.S., Overgaard, J., et al. (1997) Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer who Receive Adjuvant Chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. The New England Journal of Medicine, 337, 949-955.
http://dx.doi.org/10.1056/NEJM199710023371401

[8] Overgaard, M., Jensen, M.B., Overgaard, J., et al. (1999) Postoperative Radiotherapy in High-Risk Postmenopausal Breast-Cancer Patients Given Adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c Randomised Trial. Lancet, 353, 1641-1648.
http://dx.doi.org/10.1016/S0140-6736(98)09201-0

[9] Ragaz, J., Olivotto, I.A., Spinelli, J.J., et al. (2005) Locoregional Radiation Therapy in Patients with High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial. Journal of the National Cancer Institute, 97, 116-126.
http://dx.doi.org/10.1093/jnci/djh297

[10] 郑莹, 吴春晓, 张敏璐. 乳腺癌在中国的流行状况和疾病特征[J]. 中国癌症杂志, 2013, 23(8): 561-569.

[11] Whelan, T.J., Olivotto, I., Ackerman, I., et al. (2011) NCIC-CTG MA.20: An Intergroup Trial of Regional Nodal Irradiation in Early Breast Cancer. Journal of Clinical Oncology, 29, LBA1003.

[12] 王淑莲, 李晔雄, 宋清坤, 等. 1999-2008年中国乳腺癌根治术后放疗部位变化的临床流行病学研究[J]. 中华放射肿瘤学杂志, 2013, 22(5): 347-351.

分享
Top